PO.TB10.14 · 肿瘤生物学
食管鳞状细胞癌中肿瘤内Fusobacterium nucleatum与基质重塑及免疫排斥的关联
Association of intratumoral Fusobacterium nucleatum with stromal remodeling and immune exclusion in esophageal squamous cell carcinoma
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:Fusobacterium nucleatum(F. nucleatum)是一种口腔厌氧菌,已被发现与食管鳞状细胞癌(ESCC)的肿瘤进展和免疫抑制相关。然而,其与肿瘤微环境(TME)内基质重塑和免疫排斥的关系仍不清楚。
方法:我们对93例TCGA-ESCC病例和126例切除肿瘤进行了整合分析,结合宏基因组分析、转录组解卷积和组织病理学验证。使用Centrifuge和定量PCR确定F. nucleatum状态。通过CIBERSORT和EPIC估算免疫和基质细胞比例。对α-平滑肌肌动蛋白(alpha-SMA)和NF-κB p65(RelA)进行免疫组织化学(IHC),以评估癌症相关成纤维细胞(CAF)活化和炎症信号,并通过荧光原位杂交(FISH)在肿瘤内可视化F. nucleatum。比较了F. nucleatum阳性和阴性病例之间的临床病理变量,包括ECOG体能状态。
结果:93例TCGA-ESCC肿瘤中有23例(25%)为F. nucleatum阳性(相对丰度≥0.02%)。基因集富集分析显示,F. nucleatum阳性肿瘤中TNFα/NF-κB和上皮-间质转化通路被激活。CIBERSORT显示CD8⁺ T细胞浸润减少,而EPIC则显示CAF比例更高(0.72对0.45,P < 0.01)。在验证队列中,IHC证实F. nucleatum阳性肿瘤中alpha-SMA表达增加,与转录组结果一致。FISH在毗邻alpha-SMA阳性成纤维细胞的肿瘤细胞内鉴定出F. nucleatum信号,提示感染与基质活化之间存在空间邻近性。RelA核定位在F. nucleatum阳性肿瘤中显著更为常见,表明NF-κB被激活。同时具有强alpha-SMA表达和RelA核定位的病例在F. nucleatum阳性组中明显富集(P < 0.01)。这些发现支持这样一个模型:F. nucleatum激活NF-κB介导的细胞因子信号,促进成纤维细胞募集和基质扩张,从而促成免疫排斥。在临床上,尽管肿瘤分期相似,F. nucleatum阳性与更差的体能状态相关,提示定植可能反映全身脆弱性或口腔卫生不佳。
结论:ESCC中肿瘤内F. nucleatum与一种NF-κB激活、成纤维细胞丰富、CD8⁺ T细胞匮乏的TME相关。通过促进基质重塑和免疫排斥,F. nucleatum可能增强肿瘤侵袭性。这些发现凸显了微生物定植、基质活化和宿主状态之间的相互作用,为理解ESCC中潜在的微生物组-基质-免疫相互作用提供了见解。
查看英文原文 English abstract
Background: Fusobacterium nucleatum ( F. nucleatum ), an oral anaerobe, has been linked to tumor progression and immune suppression in esophageal squamous cell carcinoma (ESCC). However, its relationship with stromal remodeling and immune exclusion within the tumor microenvironment (TME) remains unclear.
Methods: We performed integrated analyses combining metagenomic profiling, transcriptomic deconvolution, and histopathologic validation in 93 TCGA-ESCC cases and 126 resected tumors. F. nucleatum status was determined using Centrifuge and quantitative PCR. Immune and stromal cell fractions were estimated by CIBERSORT and EPIC. Immunohistochemistry (IHC) for alpha-smooth muscle actin (alpha-SMA) and NF-κB p65 (RelA) assessed cancer-associated fibroblast (CAF) activation and inflammatory signaling, and fluorescence in situ hybridization (FISH) visualized F. nucleatum within tumors. Clinicopathologic variables, including ECOG performance status, were compared between F. nucleatum -positive and -negative cases.
Results: Twenty-three of 93 TCGA-ESCC tumors (25%) were F. nucleatum -positive (≥0.02% relative abundance). Gene set enrichment analysis revealed activation of TNFalpha/NF-κB and epithelial-mesenchymal transition pathways in F. nucleatum -positive tumors. CIBERSORT showed reduced CD8⁺ T-cell infiltration, while EPIC demonstrated a higher CAF fraction (0.72 vs. 0.45, P < 0.01). In the validation cohort, IHC confirmed increased alpha-SMA expression in F. nucleatum -positive tumors, consistent with transcriptomic results. FISH identified F. nucleatum signals within tumor cells adjacent to alpha-SMA-positive fibroblasts, suggesting spatial proximity between infection and stromal activation. Nuclear RelA localization was significantly more frequent in F. nucleatum -positive tumors, indicating NF-κB activation. Cases with both strong alpha-SMA expression and nuclear RelA were markedly enriched in the F. nucleatum -positive group (P < 0.01). These findings support a model in which F. nucleatum activates NF-κB-mediated cytokine signaling that promotes fibroblast recruitment and stromal expansion, contributing to immune exclusion. Clinically, F. nucleatum positivity was associated with poorer performance status despite similar tumor stages, suggesting colonization may reflect systemic vulnerability or impaired oral hygiene.
Conclusions: Intratumoral F. nucleatum is associated with an NF-κB-activated, fibroblast-rich, and CD8⁺ T-cell-poor TME in ESCC. By promoting stromal remodeling and immune exclusion, F. nucleatum may enhance tumor aggressiveness. These findings highlight the interplay between microbial colonization, stromal activation, and host condition, offering insight into potential microbiome-stroma-immune interactions in ESCC.
利益披露 Disclosure
T. Ofuchi, None..
Q. Hu, None..
K. Mimori, None..
M. Iwatsuki, None.